Caldera has protected our intellectual property around both the techniques (RBAS) and gene expression profiles for diagnosis/prognosis of prostate cancer by filing patent applications in the major OECD countries.

Through the course of our development, Caldera has also accumulated considerable know-how and trade secrets that include both data and analytical tools.